False-Positive Somatostatin Receptor Scintigraphy: Really?

Similar documents
Lutetium-DOTA TATE Treatment of inoperable GEP NETs

Respiratory Interactive Session. Elaine Borg

Gallium-67 Citrate in a Patient with Fever of Unknown Origin

Imaging of Neuroendocrine Metastases

Peptide Receptor Radionuclide Therapy using 177 Lu octreotate

objectives Pitfalls and Pearls in PET/CT imaging Kevin Robinson, DO Assistant Professor Department of Radiology Michigan State University

Radiology Pathology Conference

Nuclear Medicine in Oncology

FDG PET/CT STAGING OF LUNG CANCER. Dr Shakher Ramdave

Chapter 23 Clinical Efficacy of PET/CT Using

Detection of Soft Tissue Tumors on Bone Scintigraphy: Report of Four Cases

Lung. 10/24/13 Chest X-ray: 2.9 cm mass like density in the inferior lingular segment worrisome for neoplasm. Malignancy cannot be excluded.

Case Report. Ameya D. Puranik, MD, FEBNM; Harshad R. Kulkarni, MD; Aviral Singh, MD; Richard P. Baum, MD, PhD ABSTRACT

Case report. Kováčová Martina Comenius University in Bratislava Slovakia Faculty of medicine

PET/CT in lung cancer

Radiology Pathology Conference

Original article. M. Cimitan 1 *, A. Buonadonna 2, R. Cannizzaro 3, V. Canzonieri 4, E. Borsatti 1, R. Ruffo 1 & L. De Apollonia 5.

Bronchogenic Carcinoma

MEDICAL POLICY EFFECTIVE DATE: 06/21/07 REVISED DATE: 05/14/08, 04/16/09, 03/18/10, 03/17/11, 03/15/12, 02/21/13, 02/20/14, 02/19/15

October 2012 Imaging Case of the Month. Michael B. Gotway, MD Associate Editor Imaging. Department of Radiology Mayo Clinic Arizona Scottsdale, AZ

Nuclear medicine studies of the digestiv system. Zámbó Katalin Department of Nuclear Medicine

New lung lesion in a 55 year-old male treated with chemoradiation for non-small cell lung carcinoma

Neuroendocrine Tumors Positron Emission Tomography (PET) Imaging and Peptide Receptor Radionuclide Therapy

Molecular Imaging Guided Therapy: The Perfect Storm. David M Schuster, MD Emory University Department of Radiology Atlanta, GA

Mediastinal Staging. Samer Kanaan, M.D.

Theranostics in Nuclear Medicine

Chest Radiology Interpretation: Findings of Tuberculosis

Case Report Metastatic Insulinoma Managed with Radiolabeled Somatostatin Analog

Radioisotopes for staging and follow-up of prostate cancer. F. Scopinaro

Tumori Neuroendocrini - Imaging perioperatorio. Annibale Versari Medicina Nucleare, Az.Osp. S.Maria Nuova-IRCCS - Reggio Emilia

Dr. Sandip Basu Radiation Medicine Center (BARC) Tata Memorial Centre Annexe, Parel, Mumbai

Common things are common, but not always the answer

Chief Complain. For chemotherapy

Lung Cancer Imaging. Terence Z. Wong, MD,PhD. Department of Radiology Duke University Medical Center Durham, NC 9/9/09

GI CARCINOID Dr Mussawar Iqbal Consultant Oncologist Hull and East Yorkshire Hospitals NHS Trust

Nuclear oncology using SPECT and PET is able to show

INTERSTITIAL LUNG DISEASE Dr. Zulqarnain Ashraf

PULMONARY TUBERCULOSIS RADIOLOGY

Nuclear Medicine Head and Neck Region. Bán Zsuzsanna, MD University of Pécs, Department of Nuclear Medicine

Slide 1. Slide 2. Slide 3. Investigation and management of lung cancer Robert Rintoul. Epidemiology. Risk factors/aetiology

PET CT for Staging Lung Cancer

Assessing the lung and mediastinum in cancer-is tissue the issue? George Santis

An Introduction to PET Imaging in Oncology

Gallium-68-DOTA-NOC PET/CT of Patients With Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Single-Center Study

Nuclear medicine in oncology. 1. Diagnosis 2. Therapy

Pathology of Tumors of Lung Pathology of Tumors of Lung o Classify lung tumors.

GUIDELINES FOR CANCER IMAGING Lung Cancer

Lung Cancer Case Study

THORACIK RICK. Lungs. Outline and objectives Richard A. Malthaner MD MSc FRCSC FACS

2004 SNM Mid-Winter Educational Symposium

Charles Mulligan, MD, FACS, FCCP 26 March 2015

Larry Tan, MD Thoracic Surgery, HSC. Community Cancer Care Educational Conference October 27, 2017

Adjuvant therapy for thyroid cancer

Ga68 Imaging. Roland HUSTINX Division of Nuclear Medicine and Oncologic Imaging Centre Hospitalier Universitaire de Liège Belgium

Specialised Services Policy CP66: 68-gallium DOTA- peptide scanning for the Management of Neuroendocrine Tumours (NETs)

Lung Cytology: Lessons Learned from Errors in Practice

Chapter 10. Summary, conclusions and future perspectives

Bone PET/MRI : Diagnostic yield in bone metastases and malignant primitive bone tumors

Discussing feline tracheal disease

North of Scotland Cancer Network Clinical Management Guideline for Non Small Cell Lung Cancer

Lung Cancer Screening in the Midwest of the US: When Histoplasmosis Complicates the Picture

MEDICAL POLICY SUBJECT: PEPTIDE RECEPTOR RADIONUCLIDE THERAPY (PRRT)

The predicament of cancer presenting during pregnancy

Nuclear medicine in endocrinology

Preoperative Workup for Pulmonary Resection. Kristen Bridges, M.D. Richmond University Medical Center January 21, 2016

Ryan Niederkohr, M.D. Slides are not to be reproduced without permission of author

PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES

Targeted Radionuclide Therapy with 90 Y-DOTATOC in Patients with Neuroendocrine Tumors

Indications of PET/CT in oncology

Carcinoid Tumor with Localized Bronchiectasis

Tests Your Pulmonologist Might Order. Center For Cardiac Fitness Pulmonary Rehab Program The Miriam Hospital

Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors

PET-MRI in malignant bone tumours. Lars Stegger Department of Nuclear Medicine University Hospital Münster, Germany

Gastrinoma: Medical Management. Haley Gallup

Spontaneous Tumor Lysis Syndrome in Small Cell Lung Cancer

False Positive Imaging in PET-CT: When CT makes the difference Case-based

Chest XRay interpretation INTERPRETATIONS Identifications: Name & Date Technical evaluation Basic Interpretations

Pulmonary Sarcoidosis - Radiological Evaluation

An Update: Lung Cancer

PNET 3/7/2015. GI and Pancreatic NETs. The Postgraduate Course in Breast and Endocrine Surgery. Decision Tree. GI and Pancreatic NETs.

Histopathology: pulmonary pathology

MEDICAL POLICY SUBJECT: PEPTIDE RECEPTOR RADIONUCLIDE THERAPY (PRRT)

General Nuclear Medicine

Lung Cancer-a primer. Sai Yendamuri, MD Professor and Chair, Dept of Thoracic Surgery,RPCI,Buffalo

Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010

The International Association for the Study of Lung Cancer (IASLC) Lung Cancer Staging Project, Data Elements

Surgical indications: Non-malignant pulmonary diseases. Punnarerk Thongcharoen

Dosimetry in Nuclear Medicine Therapies

Lung cancer is one of the most common cancers worldwide,

Color Codes Pathology and Genetics Medicine and Clinical Pathology Surgery Imaging

Diagnostic Value of EBUS-TBNA in Various Lung Diseases (Lymphoma, Tuberculosis, Sarcoidosis)

performed to help sway the clinician in what the appropriate diagnosis is, which can substantially alter the treatment of management.

Bronchial syndrome. Atelectasis Draining bronchus Bronchiectasis

Surgical treatment of synchronous multiple neuroendocrine lung tumours (case series): is more always better?

Thoracic Surgery; An Overview

PET/CT Frequently Asked Questions

Multifocal Lung Cancer

* MILIARY MOTTLING --

Lung Cancer - Suspected

Small-cell lung cancer (SCLC) accounts for 15% to 18% of

Transcription:

Logo False-Positive Somatostatin Receptor Scintigraphy: Really? Dr. Augusto Llamas-Olier, Dr. Maria Cristina Martinez, Dr. Emperatriz Angarita, Dr. Amelia De Los Reyes Nuclear medicine department. Instituto Nacional de Cancerologia. Bogota, Colombia.

50-yr old female Was diagnosed with a right paravertebral pulmonary mass obstructing the inlet to the middle lobe. Surgical treatment: resection of middle lobe and right inferior lobe. Upon sectioning the right intermediate bronchus a mechanical suture was used to close the stump. Final diagnosis: non-functioning well-differentiated bronchial neuroendocrine tumor. Logo

Staging post surgical somatostatin receptor scintigraphy. Radiopharmaceutical: 99m Tc-HYNIC-Tyr 3 -octreotide Administered activity: 18 mci Findings: Well defined, high focal uptake in the right hilum. Post surgery

SPECT CT software fusion. Post surgical volume loss in right hemithorax No parenchymal lesion No intrabronchial mass Visible metal clips in surgical bed Focal uptake in intermediate bronchus stump

Fiberoptic bronchoscopy: otherwise unremarkable right bronchial stump. Bronchoalveolar lavage: no infectious agents, no tumor cells. Moderately reactive inflammatory process in respiratory epithelium (polymorphonuclear cells: 90%). Bronchial stump biopsy: negative for tumor involvement. Serum chromogranin A: 16 ng/ml.

Post surgery Follow-up (2 years after surgery) Follow-up scintigraphy shows no interval variation in right hilar uptake. No new lesions are depicted. Direct testing and sequential imaging results point out to a false-positive induced by chronic inflammation around surgical clips.

Teaching Points To adequately determine that a localization result is a falsepositive or true-positive requires either direct examination (by surgery, cytology or biopsy), other imaging studies to clarify the lesion or extensive follow-up and careful comparison to the clinical context to determine the true nature of the lesion.

Example of a false positive result. 28-year old male with a welldifferentiated neuroendocrine tumor of the jejunum. Staging In-111 pentetreotide depicted bilateral diffuse pulmonary uptake. The patient had concealed information about being under treatment for active tuberculosis.

Teaching Points Granulomatosis disease (sarcoidosis, tuberculosis, Wegener's) as well as both benign and malignant breast diseases are reported to possess high-affinity somatostatin receptors that bind octreotide and to be imaged on somatostatin receptor scintigraphy.

Example of a false positive result. 55-year old male with a well-differentiated neuroendocrine bronchial carcinoma of the left lung with liver metastases. A follow-up somatostatin receptor scintigraphy was practiced one year after left partial pneumonectomy and partial right hepatectomy. There is visible uptake in the thoracotomy scar (straight arrow). Notice focal uptake in a liver metastasis (arrow head).

Teaching Points Operative sites have been reported to result in false-positive localization on somatostatin receptor scintigraphy, perhaps because of activated lymphocytes or inflammatory cells that are known to possess somatostatin receptors and, in some patients, remain positive on SRS for several months after surgery.

2006 Example of a false positive result. 48-year old male with a welldifferentiated neuroendocrine bronchial carcinoma that was initially mistaken for an adenocarcinoma and treated with mediastinal radiotherapy before referral to a specialized institution. 2008 A staging somatostatin receptor scintigraphy performed shortly after revisited diagnosis showed uptake in mediastinal pleura. Repeated imaging 2 years later shows very little interval resolution.

Teaching Points Radiation pneumonitis can occur 1-8 months after treatment. From 8 months onwards, lung fibrosis may appear. Indium-111-pentetreotide scans are strongly or moderately positive in symptomatic patients examined 2-5 months after radiotherapy. The uptake mechanism of In-111-pentetreotide in areas of radiation pneumonitis remains to be elucidated. Radiation pneumonitis has been explained by early vascular alterations followed by epithelial changes and ablation of type II alveolar cells which will eventually also result in early surfactant release into the alveoli Enhanced production and release of cytokines from alveolar macrophages has been postulated as a component in the mechanism of radiation injury.

Discussion True false-positive results are neither false (because they represent somatostatin receptor-positive lesions) nor positive (because they are not related to the pathology under scrutiny). Despite its increased use, there has been only one systematic study of the occurrence of false-positive somatostatin receptor analogue localization (Gibril et al). Although several large studies report that somatostatin receptor scintigraphy has excellent specificity it is nevertheless important that these points be systematically examined.

Discussion (II) Newer radiolabeled somatostatin analogs which can be used in PET imaging, and which have a higher affinity for the somatostatin receptor, especially receptor subtype-2, have been developed. The most likely candidates to become the new standard for somatostatin receptor imaging are 68 Ga-DOTA 0 -Tyr 3 -octreotate and 68 Ga-DOTA 0 -Tyr 3 -octreotide.

Teaching Points (II) The most common causes for false positive results are: radiation pneumonitis, accessory spleen, surgical scar tissue, nodular goitre, ventral hernia, bacterial pneumonia, respiratory infections, common cold (nasal uptake), cerebrovascular accident, concomitant granulomatous disease, diffuse breast uptake and concomitant second primary tumour. False positive readings can be induced by the tracer s physiologic pathways or contamination: focal collection of stools, gallbladder uptake, adrenal uptake and urine contamination.

References Kwekkeboom DJ, Kam BL, Van Essen M, Teunissen JJM, Van Eijck CHJ, Valkema R, et al. Somatostatin receptorbased imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endoc Rel Cancer 2010;17:R53 R73. Gibril F, Reynolds JC, Chen CC, Yu F, Goebel SU, Serrano J, et al. Specificity of Somatostatin Receptor Scintigraphy: A prospective study and effects of false-positive localizations on management in patients with gastrinomas. J NucI Med 1999;40:539-553. Valdes-Olmos R, Van Zandwijk N, Boersma LJ, Hoefnagel CA, Baas P, Baars JB, et al. Radiation pneumonitis imaged with indium-111-pentetreotide. J Nucl Med 1996;37:584-585.